Linagliptin

 Linagliptin (BI-1356, trade names Tradjenta and Trajenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.

Linagliptin
(once-daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly.
Name CAS NO.
Linagliptin
Tradjenta, Trajenta(trade name)
CAS NO.668270-12-0 668270-12-0
Linagliptin Intermediate 1076-22-8
3-Methylxanthine,2,6-Dihydroxy-3-methylpurine
CAS NO.1076-22-8 1076-22-8
Linagliptin Intermediate 666816-98-4
8-bromo-7-(but-2-ynyl)-3-methyl-1H-purine-2,6(3H,7H)-dione
CAS NO.666816-98-4 666816-98-4
Linagliptin Intermediate 6972-82-3
5,6-Diamino-1-methyluracil
CAS NO.6972-82-3 6972-82-3
Linagliptin Intermediate 93703-24-3
8-bromo-3-methyl-1H-purine-2,6(3H,7H)-dione
CAS NO.93703-24-3 93703-24-3